Is plandaí Biotechnology Inc (plpl) a good stock to buy?
If you are looking for stocks with good return, Plandaí Biotechnology Inc can be a profitable investment option. Plandaí Biotechnology Inc quote is equal to 0.000300 USD at 2021-09-11. Based on our forecasts, a long-term increase is expected, the "PLPL" stock price prognosis for 2026-09-02 is 0.0364 USD.
Is plpl a publicly traded company?
Plandai Biotechnology, Inc. is a fully reporting SEC company, publicly traded on the OTC Market under the symbol, "PLPL". As such, Business, operational and financial information on PLPL is fully transparent and available to public view.
What is the plpl stock price prediction for 2026-09-02?
Based on our forecasts, a long-term increase is expected, the "PLPL" stock price prognosis for 2026-09-02 is 0.0364 USD. With a 5-year investment, the revenue is expected to be around +12039.93%. Your current $100 investment may be up to $12139.93 in 2026.
How to calculate P/E?
How to calculate restricted stock?
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
Who owns restricted shares of a company?
To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. A company's dividend expressed as a percentage of its current stock price.
Is PLPL paying dividends?
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
Signals & Forecast
PLPL is not currently paying a regular dividend.
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Monday, January 24, 2022, and so far it has fallen 0%. Further rise is indicated until a new top pivot has been found. Volume gained on the last day while the price remained unchanged. This is not a classical divergence, but the stock should be watched more closely at it may be a "turning point".
Is Plandaí Biotechnology, Inc. stock A Buy?
On the downside, the stock finds support just below today's level from accumulated volume at $0.0004. With no support from accumulated volume below today's level the risk is increased, as a drop below the support at $0 may give a huge drop in the stock price.
About Plandaí Biotechnology, Inc
Plandaí Biotechnology, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Golden Star Signal
Plandaí Biotechnology, Inc. focuses on the production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Who is the CEO of PPL?
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Is PPL a wholly owned subsidiary?
Participating on our call this morning are Vince Sorgi, PPL president and CEO; Joe Bergstein, chief financial officer; and Greg Dudkin, chief operating officer. Thank you, Andy, and good morning, everyone.
Is PPL Corp.'s Q3 earnings lower than expected?
PPL Capital Funding, Inc. ("PPL Capital Funding"), a wholly-owned subsidiary of PPL Corporation (NYSE: PPL), today announced that it has extended the Early Tender Date, the Withdrawal Deadline and the Expiration Date for its previously announced tender offers (collectively, the "Tender Offers" and each a "Tender Offer") to purchase for cash (1) any and all of its outstanding 4.200% Senior Notes due 2022, 3.500% Senior Notes due 2022, 3.400% Senior Notes due 2023 and 3.950% Senior Notes due 2024